The Effect and Mechanism of Celecoxib in Hypoxia-Induced Survivin Up-Regulation in HUVECs

Abstract

Background/Aims: To investigate the roles of hypoxia-inducible factor 1α (HIF-1α), cyclooxygenase-2 (Cox-2) and its product, Prostaglandin E2 (PGE₂), in the mechanisms underlying hypoxia-induced survivin expression in human umbilical vein endothelial cells (HUVECs) and to examine the effect of celecoxib, a selective Cox-2 inhibitor, on survivin expression. Methods: HUVECs were exposed to a normal (95% O₂) or hypoxic (3% O₂) environment for 24 hrs. We observed the localized expression of survivin, Cox-2 and HIF-1α in HUVECs using immunocytochemistry and detected the inhibitory effects of celecoxib on the growth of HUVECs using an MTT assay. mRNA and protein levels of Cox-2, HIF-1α and survivin were determined by real-time PCR and Western blot analysis under hypoxic conditions for 0, 6, 12, or 24 hrs. The time course changes of HIF-1α and survivin protein expression induced by cobalt chloride (CoCl₂) were studied using Western blot analysis. We then treated HUVECs under hypoxia for 24 hrs with celecoxib (a Cox-2 selective inhibitor), genistein (a HIF-1α inhibitor) or exogenous PGE₂ to further investigate the changes in hypoxia-induced survivin expression. Results: Following 24 hrs of hypoxic treatment, cells exhibited strongly positive survivin, HIF-1α and Cox-2 cytoplasmic staining. Celecoxib (65 μM) effectively inhibited cell proliferation under hypoxic conditions. The protein and mRNA levels of Cox-2, HIF-1α and survivin were increased under hypoxia. The patterns of HIF-1α and survivin expression induced by CoCl₂ were similar to those induced by exposure to hypoxia. Genistein partially blocked survivin expression. Celecoxib reversed the hypoxia-induced survivin expression, whereas the addition of PGE₂ partially restored this effect. Conclusions: Hypoxia-induced survivin expression in HUVECs may be mediated by dual interdependent mechanisms directly involving HIF-1α and indirectly involving the Cox-2/PGE₂ pathways. Celecoxib may offset hypoxia-induced survivin expression.

MALAT1 accelerates the development and progression of renal cell carcinoma by decreasing the expression of miR‐203 and promoting the expression of BIRC5

“…Besides, the expression of BIRC5 was induced by hypoxia, and BIRC5 promoted angiogenesis and was strongly correlated with cell proliferation . There is increasing evidence that indicated that BIRC5 is highly expressed in most human tumours and closely related to tumour progression, tumour recurrence, chemotherapy resistance and poor prognosis …”

Endothelial microvesicles in hypoxic hypoxia diseases

“…Hypoxia is the lack of oxygen supply to tissues, which results in abnormal cell metabolism and function as well as pathological morphological alterations . The aetiology of hypoxia‐related diseases is complex and can be divided into four categories: hypoxic hypoxia induced by an arterial oxygen pressure drop, circulatory hypoxia caused by tissue blood flow reduction, hemic hypoxia induced by haemoglobin reduction and dysoxidative hypoxia caused by altered bio‐oxidation of tissues .…”

Identification of an immune-related gene prognostic index for predicting survival and immunotherapy efficacy in papillary renal cell carcinoma

“…Some studies have shown that IDO1 was associated with a poor prognosis of PRCC, and IDO1 inhibitor may be effective for treating sarcomatoid/rhabdoid RCC ( Zhang et al, 2019b ; Kiyozawa et al, 2020 ). Accumulating evidence shows that BIRC5 (also known as survivin) is closely related to tumor progression, tumor progression, tumor recurrence, chemotherapy resistance and poor prognosis ( Liu et al, 2015 ; Zhang et al, 2019c ), and high expression levels of BIRC5 predicted a poor outcome for ccRCC patients ( Parker et al, 2006 ). TYRO3 is a key part of the tumor-associated macrophage (TAM) receptor-ligand complex, which are implicated in several hallmarks of cancer progression and involves in the acquisition of the resistance to sunitinib in renal cell carcinoma ( Pinato et al, 2016 ).…”